BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38641160)

  • 21. High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia.
    Heriyanto DS; Laiman V; Limantara NV; Anantawikrama WP; Yuliani FS; Cempaka R; Anwar SL
    BMC Res Notes; 2022 Dec; 15(1):369. PubMed ID: 36510281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
    Kim KB; Cabanillas ME; Lazar AJ; Williams MD; Sanders DL; Ilagan JL; Nolop K; Lee RJ; Sherman SI
    Thyroid; 2013 Oct; 23(10):1277-83. PubMed ID: 23489023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
    Wang H; Quan H; Lou L
    Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Tan J; Liu R; Zhu G; Umbricht CB; Xing M
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SH003 Enhances the Anti-cancer Effects of Dabrafenib on Lung Cancer Harboring
    Choi YJ; Chung YH; Lee K; Jeong M; Ko SG
    Anticancer Res; 2024 May; 44(5):1905-1913. PubMed ID: 38677764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-Density Lipoprotein Receptor Is a Key Driver of Aggressiveness in Thyroid Tumor Cells.
    Revilla G; Ruiz-Auladell L; Vallverdú NF; Santamaría P; Moral A; Pérez JI; Li C; Fuste V; Lerma E; Corcoy R; Pitoia F; Escolà-Gil JC; Mato E
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF
    Zeng Q; Deng Y; Zhang L; Wang W
    Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
    Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
    Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation.
    Jeong WJ; Mo JH; Park MW; Choi IJ; An SY; Jeon EH; Ahn SH
    Cancer Biol Ther; 2011 Sep; 12(5):458-65. PubMed ID: 21725210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma.
    Choi YS; Kwon H; You MH; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
    Endocr Relat Cancer; 2022 May; 29(6):307-319. PubMed ID: 35343921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer.
    Dultz LA; Dhar S; Ogilvie JB; Heller KS; Bar-Sagi D; Patel KN
    Surgery; 2013 Dec; 154(6):1239-44; discussion 1244-5. PubMed ID: 24094449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased CYP24A1 expression is associated with BRAF(V600E) mutation and advanced stages in papillary thyroid carcinoma.
    Zou M; BinHumaid FS; Alzahrani AS; Baitei EY; Al-Mohanna FA; Meyer BF; Shi Y
    Clin Endocrinol (Oxf); 2014 Jul; 81(1):109-16. PubMed ID: 24382015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imbalance in DNA repair machinery is associated with BRAF
    Lutz BS; Leguisamo NM; Cabral NK; Gloria HC; Reiter KC; Agnes G; Zanella V; Meyer ELS; Saffi J
    Mol Cell Endocrinol; 2018 Sep; 472():140-148. PubMed ID: 29229408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer.
    Xu M; Casio M; Range DE; Sosa JA; Counter CM
    Clin Cancer Res; 2018 Sep; 24(17):4271-4281. PubMed ID: 30065097
    [No Abstract]   [Full Text] [Related]  

  • 35. Hypermethylation of the RSK4 promoter associated with BRAF V600E promotes papillary thyroid carcinoma.
    Yin Y; Che K; Hu J; Hua H; Dong A; Wang J; Yu J; Zhang Q; Zhao S; Zhao Y; Wang P; Wang F; Wang Y; Chi J; Sun W
    Int J Oncol; 2020 May; 56(5):1284-1293. PubMed ID: 32319586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
    BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer.
    Zerilli M; Zito G; Martorana A; Pitrone M; Cabibi D; Cappello F; Giordano C; Rodolico V
    Mod Pathol; 2010 Aug; 23(8):1052-60. PubMed ID: 20473281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple proliferation-survival signalling pathways are simultaneously active in BRAF V600E mutated thyroid carcinomas.
    Rahman MA; Salajegheh A; Smith RA; Lam AK
    Exp Mol Pathol; 2015 Dec; 99(3):492-7. PubMed ID: 26403329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
    Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
    J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.